Zynex (NASDAQ:ZYXI) Posts Earnings Results, Misses Expectations By $0.11 EPS

Zynex (NASDAQ:ZYXI) announced its earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11), Zacks reports. The business had revenue of $45.98 million for the quarter, compared to analysts’ expectations of $53.65 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same quarter last year, the firm earned $0.04 earnings per share. Zynex updated its Q1 2025 guidance to -0.300- EPS.

Zynex Price Performance

Shares of ZYXI opened at $3.41 on Thursday. The business’s 50-day moving average is $7.62 and its two-hundred day moving average is $7.98. The company has a market capitalization of $108.59 million, a P/E ratio of 22.73 and a beta of 0.81. Zynex has a fifty-two week low of $3.17 and a fifty-two week high of $13.19. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZYXI. HC Wainwright dropped their target price on shares of Zynex from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. LADENBURG THALM/SH SH cut Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, Royal Bank of Canada lowered Zynex from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $11.00 to $5.50 in a research report on Wednesday.

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the transaction, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. The trade was a 33.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 30,000 shares of company stock valued at $227,100 in the last quarter. 52.13% of the stock is currently owned by company insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.